Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001084956 | SCV001058813 | likely benign | Peroxisome biogenesis disorder | 2024-12-16 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000676097 | SCV004161629 | likely benign | not provided | 2023-07-01 | criteria provided, single submitter | clinical testing | PEX6: BS2 |
Breakthrough Genomics, |
RCV000676097 | SCV005223804 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Mayo Clinic Laboratories, |
RCV000676097 | SCV000801837 | uncertain significance | not provided | 2017-04-24 | no assertion criteria provided | clinical testing | |
Natera, |
RCV001276738 | SCV001463266 | likely benign | Zellweger spectrum disorders | 2019-10-28 | no assertion criteria provided | clinical testing | |
Prevention |
RCV004737946 | SCV005360691 | likely benign | PEX6-related disorder | 2024-08-19 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |